Javascript must be enabled to continue!
Paroxetine: A Review
View through CrossRef
ABSTRACTParoxetine is a potent and selective serotonin reuptake inhibitor (SSRI) with currently approved indications for the treatment of depression, obsessive‐compulsive disorder, panic disorder and social phobia. It is also used in the treatment of generalized anxiety disorder, post traumatic stress disorder, premenstrual dysphoric disorder and chronic headache.Paroxetine, a phenylpiperidine derivative, is the most potent inhibitor of the reuptake of serotonin (5‐hydroxytryptamine, 5‐HT) of all the currently available antidepressants including the class of SSRIs. It is a very weak inhibitor of norepinephrine (NE) uptake but it is still more potent at this site than the other SSRIs. The selectivity of paroxetine, i.e., the ratio of inhibition of uptake of norepinephrine to serotonin (NE/5‐HT) is amongst the highest of the SSRIs. Paroxetine has little affinity for catecholaminergic, dopaminergic or histaminergic systems and by comparison with tricyclic antidepressants (TCAs) has, therefore, has a reduced propensity to cause central and autonomic side effects. Paroxetine exhibits some affinity for the muscarinic cholinergic receptor but much less than the TCAs. In addition, the adaptive changes of somatodendritic (5‐HT1A) and terminal (5‐HT1B/1D) autoreceptors observed with paroxetine are different to those observed with TCAs; it also inhibits nitric oxide synthase. It is both a substrate and an inhibitor of cytochrome isoenzyme P450 2D6. Paroxetine is well absorbed orally and undergoes extensive first pass metabolism that is partially saturable. Its metabolites are pharmacologically inactivein vivo.Steady state levels are achieved after 4–14 days and an elimination half‐life of 21 h is consistent with once‐daily dosing. There is wide inter‐individual variation in the pharmacokinetics of paroxetine in adults as well as in the young and the elderly with higher plasma concentrations and slower elimination noted in the latter. Elimination is also reduced in severe renal and hepatic impairment. Serious adverse events are, however, extremely rare even in overdose.In summary, paroxetine is well tolerated and effective in the treatment of both depressive and anxiety disorders across the age range.
Title: Paroxetine: A Review
Description:
ABSTRACTParoxetine is a potent and selective serotonin reuptake inhibitor (SSRI) with currently approved indications for the treatment of depression, obsessive‐compulsive disorder, panic disorder and social phobia.
It is also used in the treatment of generalized anxiety disorder, post traumatic stress disorder, premenstrual dysphoric disorder and chronic headache.
Paroxetine, a phenylpiperidine derivative, is the most potent inhibitor of the reuptake of serotonin (5‐hydroxytryptamine, 5‐HT) of all the currently available antidepressants including the class of SSRIs.
It is a very weak inhibitor of norepinephrine (NE) uptake but it is still more potent at this site than the other SSRIs.
The selectivity of paroxetine, i.
e.
, the ratio of inhibition of uptake of norepinephrine to serotonin (NE/5‐HT) is amongst the highest of the SSRIs.
Paroxetine has little affinity for catecholaminergic, dopaminergic or histaminergic systems and by comparison with tricyclic antidepressants (TCAs) has, therefore, has a reduced propensity to cause central and autonomic side effects.
Paroxetine exhibits some affinity for the muscarinic cholinergic receptor but much less than the TCAs.
In addition, the adaptive changes of somatodendritic (5‐HT1A) and terminal (5‐HT1B/1D) autoreceptors observed with paroxetine are different to those observed with TCAs; it also inhibits nitric oxide synthase.
It is both a substrate and an inhibitor of cytochrome isoenzyme P450 2D6.
Paroxetine is well absorbed orally and undergoes extensive first pass metabolism that is partially saturable.
Its metabolites are pharmacologically inactivein vivo.
Steady state levels are achieved after 4–14 days and an elimination half‐life of 21 h is consistent with once‐daily dosing.
There is wide inter‐individual variation in the pharmacokinetics of paroxetine in adults as well as in the young and the elderly with higher plasma concentrations and slower elimination noted in the latter.
Elimination is also reduced in severe renal and hepatic impairment.
Serious adverse events are, however, extremely rare even in overdose.
In summary, paroxetine is well tolerated and effective in the treatment of both depressive and anxiety disorders across the age range.
Related Results
Paroxetine Administration Alter some Biochemical Parameters in Male Wistar Rats Over a Systemic Period of Thirty-Five Days
Paroxetine Administration Alter some Biochemical Parameters in Male Wistar Rats Over a Systemic Period of Thirty-Five Days
Paroxetine is often used to treat patients with psychotic disorders, one of the side effects of this medication is that it causes erectile dysfunction in such individuals. There is...
Effects of chronic paroxetine treatment on dialysate serotonin in 5‐HT1B receptor knockout mice
Effects of chronic paroxetine treatment on dialysate serotonin in 5‐HT1B receptor knockout mice
AbstractThe role of serotonin (5‐HT)1B receptors in the mechanism of action of selective serotonin re‐uptake inhibitors (SSRI) was studied by using intracerebral in vivo microdialy...
Paroxetine attenuates osteoarthritis progression by regulating chondrocyte pyroptosis and inhibiting osteoclast formation
Paroxetine attenuates osteoarthritis progression by regulating chondrocyte pyroptosis and inhibiting osteoclast formation
Abstract
Background
Osteoarthritis (OA), a common chronic joint disease, is characterized by cartilage degeneration and subchondral bone reconstruction. Nuclear factor kap...
The Antidepressant Paroxetine Reduces the Cardiac Sodium Current
The Antidepressant Paroxetine Reduces the Cardiac Sodium Current
A considerable amount of literature has been published on antidepressants and cardiac ion channel dysfunction. The antidepressant paroxetine has been associated with Brugada syndro...
Paroxetine—The Antidepressant from Hell? Probably Not, But Caution Required
Paroxetine—The Antidepressant from Hell? Probably Not, But Caution Required
Paroxetine, also known by the trade names Aropax, Paxil, Pexeva, Seroxat, Sereupin and Brisdelle, was first marketed in the U.S. in 1992. Effective for major depression and various...
How Do Paroxetine and Citalopram Affect the Force of Contraction in Endothelially Investigated and Damaged Aortic Tissue?
How Do Paroxetine and Citalopram Affect the Force of Contraction in Endothelially Investigated and Damaged Aortic Tissue?
Background: Depression is common in patients with cardiovascular disease. Clinical data on the potential cardiovascular effects of the most commonly used antidepressant drugs, sero...
Specialty-type and state-level variation in paroxetine use among older adult patients
Specialty-type and state-level variation in paroxetine use among older adult patients
Abstract
Introduction
Paroxetine is an older “selective” serotonin reuptake inhibitor (SSRI) that is notable for its lack of se...
Apigenin Attenuates Paroxetine-Induced Ovarian Alterations in Female Rats
Apigenin Attenuates Paroxetine-Induced Ovarian Alterations in Female Rats
Paroxetine, a selective serotonin reuptake inhibitor commonly used to treat various psychiatric disorders, may adversely affect female reproductive function. Although apigenin has ...

